Transdermal lisuride delivery in the treatment of Parkinson's disease

40Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Transdermal delivery of dopamine agonists (DA) is a promising therapeutic concept, which aims to ameliorate frequency and intensity of motor fluctuations in patients with Parkinson's disease (PD). We treated 8 PD patients with unpredictable on-off phenomena with lisuride patches (release: 2-5 μg lisuride base/cm2/hour in mice) in addition to their preexisting antiparkinsonian drug regime up to a period of 8 days. In order to quantify the intensity and frequency of motor fluctuations, we determined the motor changing rate (MCR), which corresponds to the patient's self rating of motor function, performed every thirty minutes, divided through the number of scored intervals minus 1. Additional lisuride patch application significantly (p = 0.023) improved the MCR compared to baseline. Relevant side effects were transient skin irritations in four patients. Our observational study demonstrates the safety, tolerability and efficacy of transdermal lisuride delivery in the treatment of motor complications.

Cite

CITATION STYLE

APA

Woitalla, D., Müller, T., Benz, S., Horowski, R., & Przuntek, H. (2004). Transdermal lisuride delivery in the treatment of Parkinson’s disease. Journal of Neural Transmission, Supplement, (68), 89–95. https://doi.org/10.1007/978-3-7091-0579-5_10

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free